vs
GERMAN AMERICAN BANCORP, INC.（GABC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是GERMAN AMERICAN BANCORP, INC.的1.6倍（$207.3M vs $126.7M），GERMAN AMERICAN BANCORP, INC.净利率更高（28.2% vs -62.0%，领先90.2%），GERMAN AMERICAN BANCORP, INC.同比增速更快（39.7% vs 25.9%），GERMAN AMERICAN BANCORP, INC.自由现金流更多（$154.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 22.7%）
German American Bancorp, Inc.（股票代码：GABC）是一家美国的银行控股企业，专注于提供多元金融服务，核心业务涵盖支付卡相关服务，总部位于纽约曼哈顿下城的巴特利公园城，在金融服务领域拥有成熟的业务布局。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GABC vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $126.7M | $207.3M |
| 净利润 | $35.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 34.6% | -54.7% |
| 净利率 | 28.2% | -62.0% |
| 营收同比 | 39.7% | 25.9% |
| 净利润同比 | 53.7% | 3.5% |
| 每股收益（稀释后） | $0.98 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $126.7M | $207.3M | ||
| Q3 25 | $126.5M | $159.9M | ||
| Q2 25 | $123.2M | $166.5M | ||
| Q1 25 | $111.1M | $139.3M | ||
| Q4 24 | $90.7M | $164.6M | ||
| Q3 24 | $88.5M | $139.5M | ||
| Q2 24 | $90.5M | $147.0M | ||
| Q1 24 | $84.1M | $108.8M |
| Q4 25 | $35.7M | $-128.6M | ||
| Q3 25 | $35.1M | $-180.4M | ||
| Q2 25 | $31.4M | $-115.0M | ||
| Q1 25 | $10.5M | $-151.1M | ||
| Q4 24 | $23.2M | $-133.2M | ||
| Q3 24 | $21.0M | $-133.5M | ||
| Q2 24 | $20.5M | $-131.6M | ||
| Q1 24 | $19.0M | $-170.7M |
| Q4 25 | 34.6% | -54.7% | ||
| Q3 25 | 34.6% | -106.9% | ||
| Q2 25 | 31.8% | -64.8% | ||
| Q1 25 | 12.0% | -102.6% | ||
| Q4 24 | 31.6% | -74.3% | ||
| Q3 24 | 29.0% | -94.6% | ||
| Q2 24 | 29.4% | -79.1% | ||
| Q1 24 | 27.6% | -151.9% |
| Q4 25 | 28.2% | -62.0% | ||
| Q3 25 | 27.7% | -112.8% | ||
| Q2 25 | 25.5% | -69.0% | ||
| Q1 25 | 9.5% | -108.5% | ||
| Q4 24 | 25.6% | -80.9% | ||
| Q3 24 | 23.8% | -95.7% | ||
| Q2 24 | 22.7% | -89.5% | ||
| Q1 24 | 22.6% | -156.8% |
| Q4 25 | $0.98 | $-1.28 | ||
| Q3 25 | $0.94 | $-1.81 | ||
| Q2 25 | $0.84 | $-1.17 | ||
| Q1 25 | $0.30 | $-1.57 | ||
| Q4 24 | $0.79 | $-1.34 | ||
| Q3 24 | $0.71 | $-1.40 | ||
| Q2 24 | $0.69 | $-1.52 | ||
| Q1 24 | $0.64 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $100.0M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $8.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $100.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $114.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.0B | $144.2M | ||
| Q4 24 | $715.1M | $255.0M | ||
| Q3 24 | $744.6M | $346.8M | ||
| Q2 24 | $687.8M | $432.4M | ||
| Q1 24 | $655.3M | $140.3M |
| Q4 25 | $8.4B | $1.5B | ||
| Q3 25 | $8.4B | $1.2B | ||
| Q2 25 | $8.3B | $1.3B | ||
| Q1 25 | $8.4B | $1.3B | ||
| Q4 24 | $6.3B | $1.5B | ||
| Q3 24 | $6.3B | $1.5B | ||
| Q2 24 | $6.2B | $1.6B | ||
| Q1 24 | $6.1B | $1.3B |
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $154.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 121.6% | -48.6% |
| 资本支出强度资本支出/营收 | 4.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.46× | — |
| 过去12个月自由现金流最近4个季度 | $267.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $159.3M | $-99.8M | ||
| Q3 25 | $51.8M | $-91.4M | ||
| Q2 25 | $26.9M | $-108.3M | ||
| Q1 25 | $37.9M | $-166.5M | ||
| Q4 24 | $95.8M | $-79.3M | ||
| Q3 24 | $24.5M | $-67.0M | ||
| Q2 24 | $18.7M | $-77.0M | ||
| Q1 24 | $23.9M | $-190.7M |
| Q4 25 | $154.0M | $-100.8M | ||
| Q3 25 | $50.1M | $-92.7M | ||
| Q2 25 | $26.2M | $-110.7M | ||
| Q1 25 | $36.7M | $-167.8M | ||
| Q4 24 | $90.7M | $-79.5M | ||
| Q3 24 | $23.0M | $-68.6M | ||
| Q2 24 | $17.0M | $-79.0M | ||
| Q1 24 | $22.6M | $-193.9M |
| Q4 25 | 121.6% | -48.6% | ||
| Q3 25 | 39.6% | -58.0% | ||
| Q2 25 | 21.2% | -66.5% | ||
| Q1 25 | 33.0% | -120.5% | ||
| Q4 24 | 100.1% | -48.3% | ||
| Q3 24 | 26.0% | -49.2% | ||
| Q2 24 | 18.8% | -53.7% | ||
| Q1 24 | 26.9% | -178.2% |
| Q4 25 | 4.2% | 0.5% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 1.1% | 1.0% | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 1.8% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
| Q4 25 | 4.46× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 3.61× | — | ||
| Q4 24 | 4.13× | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 0.91× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GABC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
